Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...
SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the ...
Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated ...
Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...
Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C.
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company ...
Marvell Technology, Inc. , a leader in data infrastructure semiconductor solutions, today reported financial results for the fourth fiscal quarter and fiscal year ended February 1, 2025. Net revenue ...